CA-DENODO
29.2.2024 08:31:33 CET | Business Wire | Press release
Denodo, a leader in data management, today announced that Forrester Research, Inc. has positioned Denodo as a Leader in The Forrester Wave™: Enterprise Data Fabric, Q1 2024. According to the report, “Denodo is a great fit for customers focusing on an enterprise-wide data fabric strategy to support real-time analytics, customer 360, data engineering, data science, IoT analytics, operational insights, and predictive analytics use cases.” Denodo and 14 other vendors were evaluated across 26 criteria, including current offering, strategy, and market presence.
The complete and complimentary report, published on February 28, is available here.
The Wave revealed that while data fabric traditionally focused on read-only analytical use cases, there is a notable shift towards transactional fabric, with bidirectional read-and-write capabilities to support modern applications such as microservices and real-time customer experience. Today, enterprises are leveraging data fabric to accelerate new and emerging business cases such as customer experience, data science, IoT insights, global transactions, fraud prevention, business 360, and real-time insights.
Forrester VP, Principal Analyst and author of the report, Noel Yuhanna wrote, “Denodo Technologies delivers a world-class data fabric solution. [They have] been a longtime player in data virtualization and now support enterprise data fabric with next-generation data management capabilities. Denodo’s superior data fabric roadmap suggests a focus on advanced data integration, GenAI/LLM, vector search, faster data ingestion, automation, and self-service capabilities.”
Denodo received the highest scores possible in eight criteria, including deployment options, data access and search, data delivery, data processing and persistence, data transformation and lineage, and data integration. The report noted that reference customers like Denodo’s flexible platform, technical support, support for data mesh, data integration, and roadmap.
“This Forrester Research recognition validates, in our opinion, the value of our enterprise data fabric deployments and cloud service. Our customers use the Denodo Platform to establish a common data foundation across the IT corporate infrastructure that enables data products to be created at the speed – and with the agility – required by business users,” said Angel Viña, CEO and Founder at Denodo. “Through this Forrester report, our customers are telling us why Denodo is at the forefront of data management innovation: We simplify data integration through data virtualization technology, which eliminates unnecessary data movement; we accelerate data solutions because we create data ecosystems with true, unified semantics; we speed up time-to-production because we make it faster to access the data in distributed systems; we add self-service capabilities; and we enable new Generative AI applications by helping to create contextualized LLM models that learn from patterns in their own business data.”
With some of the best-in-class and latest innovations, the Denodo Platform:
- Provides IT organizations the flexibility to evolve their data strategies, migrate to the cloud or logically unify data assets without disrupting the business.
- Accelerates data provisioning without requiring costly replication of the data.
- Supports consistent security and governance across multiple systems.
- Enables self-service by giving business users the ability to discover, access and prepare data on their own.
Please Tweet: https://ctt.ac/di1R4
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using a logical approach to enable self-service BI, data science, hybrid/multi-cloud data integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprises and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 (US) / +44 (0) 20 7869 8053 (UK) / +65 6950 7489 (Singapore).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228251918/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
